[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532069":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":29,"collaborators":7,"id":33,"slug":7,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":36,"acronym":37,"eligibilityCriteria":38,"healthyVolunteers":39,"sex":40,"minAge":41,"maxAge":7,"enrollmentInfo":42,"targetDuration":7,"studyType":45,"phases":7,"briefSummary":46,"conditions":47,"keywords":7,"overallStatus":11,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"University Medical Center Goettingen","OTHER",null,[9],{"facility":10,"status":11,"city":12,"state":13,"zip":14,"country":15,"countryCode":16,"cosmosGeoPoint":17,"geoPoint":22,"contacts":23},"Universitätsmedizin Göttingen","RECRUITING","Göttingen","Lower Saxony","37075","Germany","DE",{"type":18,"coordinates":19},"Point",[20,21],9.93228,51.53443,{"lat":21,"lon":20},[24],{"name":25,"role":26,"phone":27,"phoneExt":7,"email":28},"Alexander Schulz, Dr. med.","CONTACT","0049 551 3967601","alexander.schulz@med.uni-goettingen.de",{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Alexander Schulz","Principal Investigator","100532069",false,"NCT06208007","Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF","ARTSPREDICTION","Inclusion Criteria:\n\nOne or more of the following criteria:\n\n* Age \\> 60 years\n* Arterial hypertension (RR systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or ≥ 2 antihypertensive drugs)\n* Diabetes mellitus Type I or II\n* Atrial fibrillation\n* Chronic kidney disease (GFR \\\u003C 60 ml\u002Fmin\u002F1,73 m2 or urine albumin ≥ 30mg\u002F24h or ACR ≥ 30 mg\u002Fg)\n* BMI ≥ 30 kg\u002Fm2\n* NYHA ≥ II\n* E\u002Fe' \\> 8\n\nExclusion Criteria:\n\n* Left ventricular ejection fraction \\\u003C 50 %\n* Significant valve disease (Grade III or higher)\n* History of interventional or surgical valve repair\n* Regional wall motion abnormalities\n* Respiratory diseases as a known cause for dyspnea\n* Atrial flutter or fibrillation during examination\n* Hypertrophic\u002Frestrictive\u002Farrhythmogenic\u002Fdilatative cardiomyopathies including cardiac amyloidosis or sarcoidosis and toxic cardiomyopathy\n* History of heart transplantation",true,"ALL","18 Years",{"count":43,"type":44},150,"ESTIMATED","OBSERVATIONAL","Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investigate the association of arterial stiffening and the development of cardiac diastolic dysfuntion and HFpEF.",[48,49],"Heart Failure With Preserved Ejection Fraction","Cardiovascular Morbidity","2024-05-08",{"date":52,"type":53},"2024-05-09","ACTUAL",{"date":55,"type":53},"2024-02-23",{"date":57,"type":44},"2028-01",{"name":5,"class":6},1]